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Case Report
Abstract
Germ cell tumor is the most common cancer among males in the 20–39 year-old age range, representing 21% of invasive cancer
diagnose. The vast majority of testicular tumors in this age range are germ cell tumors. There are two types of malignant tu-
mors, the pure seminoma cell and non-seminomatous germinal cell tumors (NGCT). We present the case of a patient who un-
derwent a testicular tumor surgery, classic seminoma stage I, receiving two cycles of adjuvant carboplatin chemotherapy. Dur-
ing the follow up, an elevation on the alpha-fetoprotein level was observed, thus the final diagnosis was adenopatic recurrence
of the Yolk Sac tumor.
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Introduction
Testicular tumors are the most common malign solid
neoplasias affecting young males, representing less than 1%
of male tumors. The number cases have a peak in the age
range 20–39 years, then decline; therefore it is considered a
prototypic malignancy of young adults. The incidence of
germ cell tumors in males is relatively steady through the
age range 20–39 years. From 2001 to 2005, the incidence of
germ cell tumor in the US was estimated to be 11.8 per
100,000 males aged 20–39.1 years. Overall, there are about
8200 new cases of testicular germ cell tumor in the United
States annually.1
There are two types of malignant tumors, the pure seminoma
cell and non-seminomatous germinal cell tumors (NGCT). In
clinical practice, three types of tumoral markers are
quantified in blood analysis: alpha-fetoprotein, (AFP), beta
subunit of chorionic gonadotropin, (hCG), and lactate
dehydrogenase (LDH). Levels of AFP and/or hCG show an
increase in 80-85% of the NGCTs, even in non-metastatic
disease. However, the hCG is elevated in less than 20% of
the seminoma cells and showing not AFP level increase in
these tumors.2 Before the development of the effective
chemotherapy, the 5-years survival rate in patients with
germinal tumors was 64% whereas this was improved to the
current 95% for seminoma cells and non-seminomatous
cells.
After the initial treatment, the follow up must be carried out
with periodic hCG and AFP determinations. An increase in
tumoral markers represents the first evidence of disease,
including those ones that have normal levels at the time of
the initial diagnosis.3 Relapsed patients with pure seminoma
stage-I after the orchiectomy can be treated with
radiotherapy (RT) or cisplatine-based chemotherapy.4 In case
of residual masses, patients must be only observed, except for
tumors larger than 3 cm, in this case, neoplasia removal will
be performed or a biopsy if the surgery was not possible.
Currently, positron emission tomography (PET) computed
axial tomography application is recommended and if the
outcome is positive (increased SUV) it is mandatory to
remove the neoplasia. Relapsed patients with CGNT stage-I
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after an orchiectomy must be treated with cisplatine
chemotherapy and underwent surgery of the residual masses,
except in cases when the primary tumor was an embrionary
carcinoma, with or without seminoma. Monitoring is
recommended in patients under chemotherapy when the
tumor volume decreased at least 90%.
Clinical case
We report the case of one patient, a 45-years-old male,
without relevant medical history, underwent for vasectomy,
showed up at the emergency service in November 2011 for
painless tumor in left testicle. Blood analysis was performed
yielding the following results, human chorionic
gonadotropin (hCG) level was 61 mU/mL (normal level<5
mU/mL), alpha-fetoprotein (AFP) level of 12 ng/mL (normal
range: 0 – 10 ng/mL) and LDH level of 494 U/L (normal
range: 230-460 U/L).
A surgery was performed, on November 18, 2011according to
germinal tumor diagnosis by left inguinal orchiectomy.
Anatomopatologic (AP) study shows a 4.8 x 2.2 cm classic
seminoma that invades both testicular membranes (T2NxMx)
without linfovascular presentation and with resection
borders free. The post-surgery analysis showed hCG 0.1
mU/mL, AFP 14 ng/mL and LDH 321 U/L levels. The
thoracic and abdominal computed axial tomography showed
no visceral or lymph node involvement.
Because of the type of tumor, a classic high risk testicular
seminoma stage-I, (larger than 4cm) with good prognosis,
the patient received two cycles of adjuvant carboplatin
(AUC7) every 21 days, finishing on January 20, 2012, and
followed by regular monitoring.
FIG. 1: Abdominal computed axial tomography May 2012:
adenopathy of 8 mm in minor axis at high grastrohepathic level
On January 2012, the blood analysis showed an AFP increase
(34.2 ng/mL). Due to this elevation, the patient was assessed
closely. A re-evaluation was performed by clinical
examination, thoracic and abdominal computed axial
tomography, PET computed axial tomography, cranial RMN,
lumbar puncture and bone marrow biopsy. The obtained
outcomes could not explain the AFP increase. The primary
tumor biopsy was reviewed by the Pathological Anatomy
Service confirming the initial diagnosis of classic seminoma.
On May 2012, the AFP showed a level of 107 ng/mL and the
computed axial tomography showed an adenopathy of 8 mm
of lower axe at the gastrohepatic high level, (Figure 1).
A High technology imaging in digestive endoscopy, (HDE),
was implemented ed and no malicious adenopathies were
noted. On July 2012, due to the rise of AFP, (2400 ng/mL),
and in absence of macroscopic disease chemotherapy was
started with BEP schedule (Cisplatin 20 mg/m² days 1-5,
Etoposide 100 mg/m² days 1-5 and Bleomycin 30 mg days 1,
8 and 15) every 21 days during 3 cycles, AFP level  was
reduced to 350 ng/mL. After two months of follow up, AFP
level increased again and computed axial tomography
showed an increase to 17 mm in the gastrohepatic
adenopathy previsouly observed (Figure 2). On 14 February
of 2013, the patient underwent a laparothomy showing an
adenopathy at the celiac trunk (2 cm) in close contact with
panchreas. The AP result was compatible with solid Yolk Sac
Tumor, with a significant AFP expression. After lymph node
metastasis surgical removal, AFP droped to 44.7 ng/mL level
and two additional cycles of carboplatin and ethoposide were
administered, currently the patient maintain this treatment.
FIG. 2: Abdominal computed axial tomography January 2013:
adenopathy of 17 mm in minor axis at high grastrohepathic level.
Discussion
In most cases of germinal tumors stage-I, a clinical follow up
is performed. The recidives incidence is around 16-20% and
the median of time is 12-18 months, and the most common
site is the retroperitoneum, followed by pelvic and lung
lymph nodes. In contrast, in this patient, the radiological
relapse happens at grastrohepatic level without other
adenopathies at retroperitoneal level. Carboplatin has an
effect in the metastatic seminoma, (although lower than
cisplatin), and with an acceptable tolerability profile. Most of
the patients with stage-I seminoma were treated with one or
two cycles or adjuvant carboplatin obtaining excellent re-
sults. The relapse index achieved by treatment is smaller
than after radiotherapy and the 5-years-survival rate is al-
most 100%, therefore it is recommended in high-risk pa-
tients, (size greater than 4 cm or with Rete testis invasion).5, 6
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In this case, the minimum AFP elevation prior and after
surgery, (12 and 14 ng/mL respectively), questioning the
non-seminomatous nature of the tumor. Although,
anatomopathological findings after over 10 histological slides
in the primary testicular tumor showeded a classic pattern
seminoma, (Figure 3), with clear lymphocitic infiltration and
lack of pseudoglandular patterns.
FIG. 3: Original tumor: classic seminoma with minimal
lymphocitical infiltration.
The immunohistochemical analysis showed a classic
immunophenotype with OCT3+and AFP-, cytokeratins- and
hCG-. However, the ganglionar metastasis showed a
different histology, showing a solid vitelline tumor with
glandular areas, (Figure 4), the immunophenotype was
completely different from the original tumor, being AFP +
(Figure 5) and showing SALL4 expression.
FIG. 4: Lymphatic ganglion: metastasis of vitelline tumor with solid
pattern and in the glandular part. Observe hyaline globules.
FIG. 5: Viteline tumor, glandular area with clear secretion of
alpha-fetoprotein.
The classical conception that seminoma cannot evolve
towards other tumoral types has been controversial, previous
data showing the seminoma pluripotenciality with similar
characteristic to primary germinal cells. This evidence is
supported by immunohistochemical and ultra-structural
studies that showed somatic differentiating aspects,
(cytokeratin, blood antigens), in primitive germinal cells of
the seminoma. This assumption is showed for both testicular
and ovarian germinomas.7, 8, 9 This conversion from primary
germinal cells is just a particular type of maturation process,
in this case induced by chemotherapy or spontaneously.
Conclusion
The relapse of classic seminoma stage-I is rare and usually
appears in retroperitoneum or lungs. In case of metastasis,
the histology is similar to primary tumor but, occasionally, it
can suffer cellular transformation, induced by
chemotherapy. In other cases, the transformation occurs on
the histology alone, without chemotherapy.
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